Join to View Full Profile
300 Halket StreetSuite 4628Pittsburgh, PA 15213
Phone+1 412-641-6500
Fax+1 412-641-2256
Dr. Brufsky is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Mass General Brigham/Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 1992 - 1995- Mass General Brigham/Brigham and Women's HospitalResidency, Internal Medicine, 1990 - 1992
Uconn School Of MedicineClass of 1990
Certifications & Licensure
PA State Medical License 1996 - 2026
FL State Medical License 2012 - 2020
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- America's Top Doctors Castle Connolly, 2009-2014
- America's Top Doctors for Cancer Castle Connolly, 2005-2013
- Pittsburgh Magazine Castle Connolly, 2005-2009
- Join now to see all
Clinical Trials
- Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy Start of enrollment: 2008 Nov 10
- Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer Start of enrollment: 2011 Jan 15
- Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer Start of enrollment: 2011 Jan 06
- Join now to see all
Publications & Presentations
PubMed
- Overall Survival With Palbociclib and Aromatase Inhibitor Versus Aromatase Inhibitor Alone in Older Patients With HR+/HER2- Metastatic Breast Cancer.Adam M Brufsky, Rickard Sandin, Stella Stergiopoulos, Connie Chen, Siddharth Karanth
Cancer Medicine. 2025-04-01 - Treatment with palbociclib and an aromatase inhibitor for people with hormone receptor-positive/ human epidermal growth factor receptor 2-negative metastatic breast ca...Adam Brufsky, Xianchen Liu, Benjamin Li, Lynn McRoy, Connie Chen
Future Oncology. 2025-03-30 - Impact of adding palbociclib on treatment adherence to ongoing adjuvant endocrine treatment in the global randomized PALLAS randomized trial in patients with early bre...Eileen Shinn, David Zahrieh, Angela DeMichele, Nick Zdenkowski, Julie Lemieux
Breast Cancer Research and Treatment. 2025-03-27
Journal Articles
- Molecular Mechanisms Linking High Body Mass Index to Breast Cancer Etiology in Post-Menopausal Breast Tumor and Tumor-Adjacent TissuesAdam M Brufsky, Tari A King, Susan B Brown, Breast Cancer Research and Treatment
- Nab-Paclitaxel plus Carboplatin or Gemcitabine vs Gemcitabine plus Carboplatin as First-Line Treatment for Patients with Triple-Negative Metastatic Breast Cancer: Resu...H Ali, A Brufsky, M Shtivelband, S Gluck, J Miller, R Young, Annals of Oncology
- Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast CancerMatthew P Goetz, Thomas J Saphner, Joseph A Sparano, Lynne I Wagner, Peter M Ravdin, Daniel F Hayes, Adam M Brufsky, Della F Makower, Sunil S Badve, Robert J Gray, Wil..., The New England Journal of Medicine
Press Mentions
Improving Tailored Treatment Plans in HR+, HER2- Early Breast CancerDecember 20th, 2024- Sticking with CDK4/6 Inhibitors for Breast Cancer Wins in Post-Progression SettingDecember 20th, 2024
- Agendia Unveils New Real-World-Evidence from FLEX, Highlighting the Expanding Utility of MammaPrint® and BluePrint® for Predicting Neoadjuvant Chemosensitivity and Potential Resistance to CDK4/6 Inhibition in Early-Stage Breast Cancer at SABCS 2024December 12th, 2024
- Join now to see all
Grant Support
- NCI NCTN-Network Lead Academic Participating Site at UPMC Hillman Cancer CenterUNIVERSITY OF PITTSBURGH AT PITTSBURGH2019–2025
- Safety Study Of Recombinant Monoclonal AntibodyNational Center For Research Resources1999–2002
- Rhumabher2/Cyclophosphamide/Doxorubicin And Placebo/Cyclophosphamide/DoxorucinbNational Center For Research Resources1998–2002
- Recombinant Humanized Anti-185her2 Monoclonal Antibody In Breast CancerNational Center For Research Resources1998–2002
- Liposomal Annamycin In Taxane Resistant Breast CancerNational Center For Research Resources1999–2000
- Androgen Receptor Associated Proteins In Prostate CancerNational Cancer Institute1996–1998
- Androgen Receptor Associated Proteins In Prostate CancerNational Cancer Institute1995
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
